multiple myeloma
Conditions
Interventions
auto-HSCT followed by reduced-intensity allotransplantation from related donor
auto-HSCT followed by reduced intensity allotransplantation using cord blood
Sponsors
The university of Tokyo Hospital,department of hematology and oncology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Meet all three criteria of IMWG 2.PS 0 to 2(including patients with PS 3 to 4 because of only bone pain) 3.1.VC greater than 0.8,FEV1 greater than 0.7,normal diffusing capacity,PaO2 greater than 80mmHg,PaCO2 less than 45mmHg,SaO2 greater than 0.96 3.2.no abnormal findings in echocardiography, EF greater than 0.55 3.3.Within two fold of normal value in T.Bil G-GTP ALP GOT GPT 3.4.CCr greater than 50ml per min 3.5.Without active infection
Exclusion criteria
Exclusion criteria: 1.Patients who recall approval 2.When stem cell source becomes not available 3.Patients with another severe disease 4.Patients who had received chemotherapy for maligancies other than multipul myeloma 5.Patients who is recognized as inadaptable for this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| survival rate of patients at 100 days from allotransplantation | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival, disease free survival and cummulative incidence of acute and chronic GVHD | — |
Countries
Japan
Contacts
Public ContactYoichi Imai
The university of Tokyo Hospital Hematology and Oncology
Outcome results
None listed